JP2011505371A - 抗−ｒｇ−１抗体の複合体 - Google Patents

抗−ｒｇ−１抗体の複合体 Download PDF

Info

Publication number
JP2011505371A
JP2011505371A JP2010536173A JP2010536173A JP2011505371A JP 2011505371 A JP2011505371 A JP 2011505371A JP 2010536173 A JP2010536173 A JP 2010536173A JP 2010536173 A JP2010536173 A JP 2010536173A JP 2011505371 A JP2011505371 A JP 2011505371A
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010536173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505371A5 (OSRAM
Inventor
デイビッド・ジェイ・キング
ジョナサン・エイ・テレット
サンジーブ・ギャングウォー
ジョセフィーン・エム・カーダレリ
チェタナ・ラオ−ナイク
チン・パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011505371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2011505371A publication Critical patent/JP2011505371A/ja
Publication of JP2011505371A5 publication Critical patent/JP2011505371A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2010536173A 2007-11-30 2008-11-26 抗−ｒｇ−１抗体の複合体 Withdrawn JP2011505371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30
PCT/US2008/084899 WO2009073524A2 (en) 2007-11-30 2008-11-26 Conjugates of anti-rg-1 antibodies

Publications (2)

Publication Number Publication Date
JP2011505371A true JP2011505371A (ja) 2011-02-24
JP2011505371A5 JP2011505371A5 (OSRAM) 2011-11-04

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536173A Withdrawn JP2011505371A (ja) 2007-11-30 2008-11-26 抗−ｒｇ−１抗体の複合体

Country Status (18)

Country Link
US (1) US20110020329A1 (OSRAM)
EP (1) EP2211908A2 (OSRAM)
JP (1) JP2011505371A (OSRAM)
KR (1) KR20100101122A (OSRAM)
CN (1) CN101951960A (OSRAM)
AR (1) AR069746A1 (OSRAM)
AU (1) AU2008331507A1 (OSRAM)
BR (1) BRPI0819765A2 (OSRAM)
CA (1) CA2707443A1 (OSRAM)
CL (1) CL2008003525A1 (OSRAM)
CO (1) CO6210734A2 (OSRAM)
EA (1) EA201000921A1 (OSRAM)
IL (1) IL206060A0 (OSRAM)
MX (1) MX2010005683A (OSRAM)
NZ (1) NZ586514A (OSRAM)
TW (1) TW200930407A (OSRAM)
WO (1) WO2009073524A2 (OSRAM)
ZA (1) ZA201003729B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017510548A (ja) * 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570990C (en) * 2004-07-16 2014-01-21 Micromet Ag Expression-enhanced polypeptides
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
HUE030846T2 (en) 2010-04-21 2017-06-28 Syntarga Bv Conjugates of cc-1065 analogs and bifunctional linkers
JP6082344B2 (ja) * 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
LT3092010T (lt) 2014-01-10 2018-10-25 Synthon Biopharmaceuticals B.V. Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų
JP7113071B2 (ja) * 2017-07-31 2022-08-04 トリシュラ セラピューティクス， インコーポレイテッド 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
CA2078118C (en) * 1990-04-25 1999-11-16 Paul A. Aristoff Cc-1065 analogs
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE271557T1 (de) * 1994-04-22 2004-08-15 Kyowa Hakko Kogyo Kk Dc-89 derivat
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
CN1463270A (zh) * 2001-05-31 2003-12-24 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
CA2459308A1 (en) * 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
UY28424A1 (es) * 2003-07-22 2005-02-28 Schering Ag Anticuerpos rgi y usos de los mismos.
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
MXPA06013413A (es) * 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2416136T3 (es) * 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP2027153B1 (en) * 2006-05-25 2014-04-30 Bayer Intellectual Property GmbH Dimeric molecular complexes

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017128571A (ja) * 2011-05-26 2017-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017510548A (ja) * 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途

Also Published As

Publication number Publication date
MX2010005683A (es) 2010-06-11
CN101951960A (zh) 2011-01-19
WO2009073524A3 (en) 2009-12-10
TW200930407A (en) 2009-07-16
ZA201003729B (en) 2011-08-31
BRPI0819765A2 (pt) 2015-05-05
CL2008003525A1 (es) 2010-01-22
AU2008331507A1 (en) 2009-06-11
IL206060A0 (en) 2010-11-30
EA201000921A1 (ru) 2010-12-30
AR069746A1 (es) 2010-02-17
WO2009073524A2 (en) 2009-06-11
NZ586514A (en) 2012-05-25
CO6210734A2 (es) 2010-10-20
US20110020329A1 (en) 2011-01-27
KR20100101122A (ko) 2010-09-16
CA2707443A1 (en) 2009-06-11
EP2211908A2 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
US8865875B2 (en) Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US8399623B2 (en) Human antibodies that bind mesothelin, and uses thereof
US20120027782A1 (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
US8481683B2 (en) Human antibodies that bind CD22 and uses thereof
US20110085970A1 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20100150950A1 (en) Human antibodies that bind cd70 and uses thereof
US20100104509A1 (en) Human antibodies that bind cd19 and uses thereof
US20090162372A1 (en) Fibronectin ed-b antibodies, conjugates thereof, and methods of use
US20110020329A1 (en) Conjugates of anti-rg-1 antibodies
HK1140943B (en) Human antibodies that bind mesothelin, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110913

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121017